TODAY今日发布Cardiovasc?Drugs?TherEarlyRecent,Mar04,今日发布04篇HeartandVesselsEarlyRecent,Mar04,今日发布01篇HeartFailRevEarlyRecent,Mar04,今日发布01篇IntJCardiovasc?ImagingEarlyRecent,Mar04,今日发布01篇DerKardiologeEarlyRecent,Mar04,今日发布01篇ClinResCardiolEarlyRecent,Mar04,今日发布01篇JEchocardiogrEarlyRecent,Mar04,今日发布01篇JThromb?ThrombolysisEarlyRecent,Mar05,今日发布02篇RECOMMEND推荐阅读01首次出现COVID-19患者的静脉血栓栓塞发生率和死亡率JThromb?ThrombolysisArticleDimitriosGiannis,MatthewA.Barish,etc.2小时前等58用户推荐阅读本文Venousthromboembolism(VTE)hasemergedasanimportantissueinpatientswithCOVID-19.?Thepurposeofthisstudyistoidentify?the?incidenceofVTEandmortalityinCOVID-19patientsinitiallypresentingtoalargehealthsystem.Ourretrospectivestudyincludedadult?patients(excludingpatientspresentingwithobstetric/gynecologicconditions)acrossamultihospitalhealthsystemintheNewYork?Metropolitan?RegionfromMarch1-April27,.?VTEandmortalityrateswithin8hofassessmentweredescribed.?In10,adultswithCOVID-19,patients(1.09%)werediagnosed?withsymptomaticVTE(pulmonaryembolism,17deepveinthrombosisevents)and28patients(0.26%)diedduringinitialassessment.Amongthesepatients,64.4%weremales,56.8%were60?yearsorolder,15.1%hadaBMI??35,and11.6%wereadmittedtotheintensivecareunit.Comorbiditiesincludedhypertension(46.6%),diabetes(24.7%),hyperlipidemia(14.4%),chroniclungdisease(12.3%),coronaryarterydisease(11.0%),andpriorVTE(7.5%).Keymedicationsincludedcorticosteroids(22.6%),statins(21.2%),antiplatelets(20.6%),andanticoagulants(20.6%).HighestD-Dimerwasgreaterthansixtimestheupperlimitofnormalin51.4%.StatinandantiplateletusewereassociatedwithdecreasedVTEormortality(eachp??0.01).InCOVID-19patientswhoinitiallypresentedtoalargemultihospitalhealthsystem,the?overallsymptomaticVTEandmortality?ratewasover1.0%.StatinandantiplateletusewereassociatedwithdecreasedVTEormortality.ThepotentialbenefitsofantithromboticsinhighriskCOVID-19patientsduringthepre-hospitalizationperioddeservesstudy.静脉血栓栓塞（VTE）已成为COVID-19患者的一个重要问题。本研究的目的是确定最初出现在大型卫生系统的COVID-19患者VTE的发生率和死亡率。我们的回顾性研究包括年3月1日至4月27日医院医疗系统中的成人患者（不包括产科/妇科疾病患者）。描述了评估后8小时内的VTE和死亡率。在10例COVID-19成人中，例（1.09%）患者被诊断为症状性VTE（例肺栓塞，17例深静脉血栓事件），28例（0.26%）患者在初始评估期间死亡。在这名患者中，64.4%为男性，56.8%为60岁或以上，15.1%的患者体重指数35，11.6%的患者入住重症监护室。共病包括高血压（46.6%）、糖尿病（24.7%）、高脂血症（14.4%）、慢性肺病（12.3%）、冠心病（11.0%）和既往静脉血栓栓塞（7.5%）。主要药物包括皮质类固醇（22.6%）、他汀类（21.2%）、抗血小板（20.6%）和抗凝剂（20.6%）。D-二聚体最高值大于正常值上限的6倍（51.4%）。他汀类药物和抗血小板药物的使用与VTE或死亡率的降低相关（p均0.01）。在医院医疗系统的COVID-19患者中，整体症状性VTE和死亡率超过1.0%。他汀类药物和抗血小板治疗与VTE或死亡率降低相关。高危COVID-19患者住院前应用抗血栓药物的潜在益处值得研究。扫描
转载请注明：http://www.jinpaidaiban.com/xjyzllc/6649.html
